Alliancebernstein L.P. Purchases 136,633 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Alliancebernstein L.P. grew its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,159,776 shares of the company's stock after buying an additional 136,633 shares during the period. Alliancebernstein L.P. owned approximately 3.92% of Dianthus Therapeutics worth $25,283,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Wellington Management Group LLP increased its position in shares of Dianthus Therapeutics by 12.2% during the 4th quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after purchasing an additional 6,552 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Dianthus Therapeutics by 14.0% during the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock worth $264,000 after buying an additional 1,490 shares during the period. KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics during the fourth quarter valued at $33,000. American Century Companies Inc. increased its position in Dianthus Therapeutics by 3.8% during the fourth quarter. American Century Companies Inc. now owns 43,996 shares of the company's stock valued at $959,000 after acquiring an additional 1,629 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $201,000. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DNTH has been the topic of several analyst reports. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Dianthus Therapeutics has an average rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Stock Up 12.9 %

Shares of DNTH stock traded up $2.01 on Friday, hitting $17.61. The stock had a trading volume of 304,304 shares, compared to its average volume of 259,482. The company has a market cap of $565.72 million, a PE ratio of -7.04 and a beta of 1.62. The business has a 50 day moving average price of $20.67 and a 200 day moving average price of $23.38. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.